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An inactivating mutation in the human CCR5 gene reduces the risk of HIV-1 infection in individuals with homozygous alleles.
We explored whether genetic immunization would induce an immune response directed to CCR5 structures and if immuno-
logical tolerance toward endogenous CCR5 could be broken. We also studied whether this immunization approach could
protect cynomolgus monkeys from an infection, with SIVsm, which primarily uses CCR5 as a coreceptor. Epidermal but not
intramuscular delivery of the CCR5 gene to mice elicited strong IgG antibody binding responses to CCR5. Intramucosal
immunization of cynomolgus macaques with CCR5 DNA followed by boosts with CCR5 peptides induced prominent IgG and
IgA antibody responses in serum and vaginal washings. The CCR5-specific antibodies neutralized the infectivity of primary
human R5 HIV-1 strains, and the macaque SIVsm but not that of a tissue culture-adapted X4 HIV-1 strain. The consecutive
CCR5 gene and CCR5 peptide immunizations induced B- and T-cell responses to peptides representing both human and
macaque amino acid sequences of the respective CCR5 proteins. This indicates that tolerance was broken against
endogenous macaque CCR5, which has a 98% homology to the human CCR5 gene. After the final boost, the vaccinated
monkeys together with two control monkeys were challenged with SIVsm. Neither protection against nor enhancement of
SIVsm infection was achieved. © 2000 Academic Press
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Human and simian immunodeficiency viruses (HIV-1
and SIV) use the CD4 receptor to enter their target
cells. In addition, they use a number of different G-
protein-coupled chemokine receptors. HIV-1 mainly
uses the coreceptors CCR5 and CXCR4. All HIV-1
strains described to date use one or both of these
receptors. CCR5 is used by the macrophage-tropic
(R5) HIV-1 isolates and CXCR4 serves as a fusion
cofactor for entry of T-cell tropic (X4) HIV-1 isolates.
Infection of macaques with SIV provides one of the
best models for HIV pathogenesis in humans. In ad-
dition to CCR5, SIV has been shown to use the orphan
receptors BOB/gpr15 and Bonzo/STRL33 (Deng et al.,
1997; Edinger et al., 1998; Farzan et al., 1997). Recently
it was demonstrated that some SIV isolates also utilize
CXCR4 (Owen et al., 2000).
CCR5 is the coreceptor preferentially used by HIV-1 in
primary infection of human macrophages and lympho-
cytes (Deng et al., 1996). A 32-bp deletion in the CCR5
gene prevents the CCR5 protein from being expressed
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400on the cell surface, but this deletion has no obvious
effect on the immunocompetence of the affected individ-
uals. Persons homozygous for the 32-bp deletion in
CCR5 are protected against primary HIV-1 infection
(Huang et al., 1996), and individuals heterozygous for the
deletion show a slow early course of infection (Bratt et
al., 1997). These findings indicate that blockage of the
CCR5 receptor by drugs or antibodies may confer in vivo
protection against primary HIV-1 infection.
The natural CCR5 binding chemokines RANTES, MIP-1
alpha, and MIP-1 beta are major HIV-1-suppressive fac-
tors (Cocchi et al., 1995). Chemokine derivatives like
AOP)-RANTES (Simmons et al., 1997) have been shown
o block HIV-1 infection of cells in vitro. RANTES also
ontributes to protection from SIV infection in vivo
Ahmed et al., 1999). Monoclonal antibodies directed
oward the CCR5 receptor can efficiently block the infec-
ivity of several M-tropic and dual-tropic HIV-1 strains in
itro (Olson et al., 1999; Wu et al., 1997a,b). Similarly,
nhibition of a macrophage-tropic HIV-1-derived enve-
ope glycoprotein gp120 binding to CCR5 could be
chieved with monoclonal antibodies recognizing either
he second extracellular loop or the N-terminal region of
he CCR5 protein (Wu et al., 1997a). The CCR5 receptor
as also been reported to act as an alloantigen in indi-
iduals homozygous for the D32 CCR5 deletion; serum
rom these individuals inhibited infection of peripheral
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401IMMUNE RESPONSES AGAINST THE HIV-1 CORECEPTOR CCR5blood lymphocytes by R5 viruses using CCR5 but not X4
viruses using the CXCR4 receptor (Ditzel et al., 1998).
Genetic immunization confers the advantage of pre-
senting antigens in a conformationally native way and
induces effective humoral and cellular immune re-
sponses against a variety of immunogens (Robinson and
Torres, 1997; Wahren and Brytting, 1997). DNA-based
immunization has been shown to induce anti-CD4 anti-
bodies directed primarily to native epitopes (Attanasio et
l., 1997). Furthermore, rhesus macaques immunized
ith recombinant soluble CD4 have been shown to de-
elop anti-self CD4 antibody responses with anti HIV-1
ctivity (Watanabe et al., 1991), indicating that immuniza-
ion with an HIV-1 receptor may be a feasible way to
reate an HIV-1 immune defense. Recently it was shown
hat a monoclonal antibody directed against the CD4
eceptor complex had broad neutralizing activity against
IV-1 and provided postexposure prophylaxis to chim-
anzees (Wang et al., 1999).
The aim of this study was to investigate the use of the
CR5 gene as an immunogen. We wanted to induce sys-
emic and local IgG and IgA antibody responses toward
arts of the CCR5 protein that are important for inhibition of
nfection. We have recently shown that a DNA-based jet
mmunization induces both systemic and local IgG and IgA
ntibodies (Lundholm et al., 1999). Here we describe ge-
etic immunization of cynomolgus macaques with the hu-
an CCR5 gene together with human GM-CSF protein. We
how that DNA immunization with the human CCR5 gene
nduces antibodies that are reactive both with the human
nd macaque CCR5 and block HIV-1 infection in vitro but
ot in vivo.
RESULTS
xpression of CCR5 from pcDNA3-CCR5 and
cDNA3-tet.CCR5
Expression and localization of the CCR5 and tet.CCR5
roteins were analyzed in transfected CHO cells (Fig. 1).
strong membrane fluorescence was observed in the
ransfected cells, which confirms the protein expression
rom both plasmids.
CR5-specific antibody and cellular immune
esponses in mice
To induce strong CCR5-specific antibody responses,
e decided to try several adjuvants and immunization
outes known to stimulate antibody production. The
CR5 gene alone or fused to a promiscuous T-helper cell
pitope from the tetanus toxin (Chin et al., 1994; Kumar et
l., 1992; Panina-Bordignon et al., 1989) was adminis-
tered together with murine GM-CSF or IL-4 genes. After
the third immunization, immune responses to the N-
terminus of CCR5 (Peptide N1, Table 1) were strong in
both groups of gene gun immunized mice (Groups G andH, Fig. 2). Moderately strong responses were measured
toward the second extracellular loop of CCR5 (peptide
X2.1, Table 1) in both groups of gene gun immunized
mice. Intramuscular immunization (Groups A–F) did not
induce any significant CCR5-specific antibody responses
even after three immunizations with 100 mg of tet.CCR5
DNA and GM-CSF (represented by Group D, Fig. 2).
A similar response pattern was seen when induction of
T-cell responses against regions of CCR5 were measured
(Table 2). Epidermal immunization by gene gun induced
moderate but significant T-cell proliferative responses to-
gether with pCI-GM-CSF against the N-terminus, first, sec-
ond, and third extracellular loops of the CCR5 protein
(group G, Table 2). When the IL-4 plasmid was added,
response was measurable to the N-terminus and first ex-
tracellular loop of CCR5 (Group H, Table 2). Intramuscular
immunization did not induce positive T-cell proliferative
responses, regardless of whether the pcDNA-CCR5 plas-
mid was coinjected with the plasmid pCI-GM-CSF (Group
D, Table 2) or with pCI-IL-4 (data not shown).
Neutralization capacity of sera from CCR5 immunized
mice
Pooled sera from mice in Groups G, H, and D were
tested in a neutralization assay. Surprisingly, sera from
these groups did not show any neutralizing effect (data
not shown), despite the high CCR5-specific antibody
binding titers in Groups G and H.
CCR5-specific antibody and cellular immune
responses in cynomolgus macaques
We reasoned that a strong local CCR5-specific IgG and
IgA mucosal response is optimal for the prevention of
FIG. 1. Transient expression of CCR5 (A) and tet.CCR5 (B). Indirect
immunofluorescence was performed on CHO cells transfected with the
pcDNA3-CCR5 or pcDNA3-tet.CCR5 constructs. CHO cells constitu-
tively expressing the human CCR5 protein (CHO-CCR5) were used as
a positive control (C).primary HIV-1 infection at mucosal sites. Furthermore, we
wanted to break tolerance toward the endogenous ma-
rs. The
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402 ZUBER ET AL.caque CCR5 receptor. Mucosal and systemic CCR5-spe-
cific antibody responses were therefore studied. Two cyno-
molgus macaques were immunized in the rectal mucosa
with pcDNA3-CCR5 together with recombinant human GM-
CSF protein, then boosted twice with the same combina-
tion. The second boost contained pcDNA3-tet.CCR5. To
enhance CCR5-specific antibody responses, the macaques
were further boosted twice with peptides representing the
N-terminus, the first and the second extracellular loops of
the human CCR5 protein.
IgG reactivity to human and macaque CCR5
sequences
Antibody responses toward the human and the ma-
caque CCR5 proteins were measured using peptides
and by neutralization of HIV-1 (Figs. 3 and 4).
Antibody responses directed to the human and ma-
caque CCR5 peptides (N1, X2.1, N1c, and X2.1c) (Table 1)
T
Aminoacids of Pep
CCR5 position
N-terminus human CCR5
N-terminus cynomolgus macaque CCR5
N-terminus human CCR5
N-terminus human CCR5
1st extracellular loop human CCR5
2nd extracellular loop human CCR5
2nd extracellular loop cynomolgus macaque CCR5
2nd extracellular loop human CCR5
3rd extracellular loop human CCR5
Control peptides
a Peptides used for boosting are shown in bold and underlined lette
b Amino acids that differ between the human and cynomolgus maca
FIG. 2. Time course of antibody response against the human CCR5
rotein in three groups of immunized BALB/c mice (n 5 5). Stars
indicate immunization events. Sera were diluted 1/50, the response
against the N-terminal part of CCR5 (aa 1–20) represented by a linear
peptide (N1, Table 1) was measured by ELISA.were analyzed. After the first DNA boost, both immunized
animals developed significant IgG titers toward the pep-
tides N1, N1c, X2.1, and X2.1c (Figs. 3 and 4A). The
response toward N1 decreased 4 weeks after the DNA
immunization, while responses toward N1c, X2.1, and
X2.1c persisted (Fig. 3). Following the first peptide boost,
both animals reacted toward all four tested peptides. By
the second peptide boost, the titers increased by one log
against the X2.1 and X2.1c peptides and by several logs
against the N-terminal peptides (Fig. 3).
In vitro IgG synthesis, IgA, and neutralization
responses
The in vitro IgG synthesis from antigen-stimulated pe-
ripheral lymphocytes was measured after the last immu-
sed in the Study
eptidesa Aminoacid sequenceb
MDYQVSSPIYDINYYTSEPC
MDYQVSSPTYDIDYYTSEPC
DINYYTSEPCQKINVKQIAA
N2 MDYQVSSPIYDINYYTSEPCQKINVKQIAA
HYLAAQWDFGNTMC
FTRSQKEGLHYTCSSHFPYS
c FTRSQREGLHYTCSSHFPYS
YTCSSHFPYSQYQFWKNFQT
QEFFGLNNCSSSNRLDQAM
R4 N MEGISIYTSDNYTEEMGSGD
R4 I1 LVMGYQKKLRSMTDK
3 PEGTRQARRNRRRRWRERQR
5 STYLGRSAEPVPLQLPPLER
letter c indicates macaque peptides.
R5 sequences are shown in bold letters.
TABLE 2
T-Cell Proliferation Mapped in Vitro with Peptides of CCR5:
Frequency of Responding Mice (SI Range)a
CCR5 peptides
Group G
Group H
Group D
pcDNA3-
tet.CCR5 1
pCI-GM-CSF
Gene gun
pcDNA3-
tet.CCR5 1
pCI-GM-CSF
1 pCI-IL-4
Gene gun
pcDNA3-
tet.CCR5 1
pCI-GM-CSF
intramuscularly
N-terminus1 2/5 (2.6–4.0) 1/5 (3.5) 0/5
st extracellular loop2 2/5 (2.8–3.7) 2/5 (2.5) 0/5
nd extracellular
loop3 2/5 (2.2–4.4) 0/5 0/5
rd extracellular loop4 1/5 (2.7) 0/5 0/5
oncanavalin-A 5/5 (310–13) 5/5 (55–10) 5/5 (922–21)
a A more than twofold SI was considered positive.ABLE 1
tides U
CCR5 p
N1
N1c
N2
N1/
X1
X2.1
X2.1
X2.2
X3
CXC
CXC
Rev
Rev1 Pooled results from stimulations with peptides N1, N2, and N1/N2,
2 peptide X1, 3 peptides X2.1 and X2.2, and 4 peptide X3.
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403IMMUNE RESPONSES AGAINST THE HIV-1 CORECEPTOR CCR5nization (Fig. 4D). The antibody responses could be
mapped to peptides representing the whole CCR5 pro-
tein. Both macaques responded strongly against the N-
erminal peptide and the first- and second-extracellular
oop peptides of human CCR5. The strongest response
as mapped to the first part of the Nalterminus (aa 1–20).
Two weeks after the initial injection of DNA, both
nimals had significant IgG and IgA titers toward peptide
1 in serum (Figs. 4A and 4B). Ten days after the first
NA boost, IgG and IgA responses against N1 increased
n both monkeys. IgA titers against N1decreased below
utoff levels after the second DNA boost for Monkey U9,
ut persisted in Monkey B189. IgG titers in both animals
ecreased after the second DNA boost.
To increase the CCR5 binding titers, we boosted the
onkeys 13 weeks after the second DNA boost with
eptides representing external parts of CCR5. Following
oth peptide boosts, the IgG and IgA titers toward all
ested peptides increased substantially for both ma-
aques (Fig. 4). After the second peptide boost, Monkeys
FIG. 3. Time course of serum antibody response directed toward the
N-terminus or second extracellular loop of human and macaque CCR5.
Arrows indicate immunization events. Antibody titers toward peptides
(Table 1) were determined using peptide ELISA, with a cutoff of 4 times
the reactivity of proimmunization serum.9 and B189 had IgG binding titers against N1 of 130,000
nd 18,000, respectively. The IgA titers against N1 in-
8
rreased to 30 for B189 and to 600 for U9. IgA in vaginal
ashings from both macaques was measurable after
hree DNA immunizations and two peptide boosts (Fig.
C). In conclusion, immunization of macaques with the
uman CCR5 gene induced new antibody responses to
oth the human CCR5 protein and the endogenous ma-
aque CCR5 protein.
eutralization capacity of sera from CCR5-immunized
onkeys
The capacity of serum to block HIV-1 infection of hu-
an peripheral blood lymphocytes (PBL) was analyzed
y using two primary R5 HIV-1 strains (J2234 and J562)
erived from asymptomatic HIV-1 patients and the labo-
atory-adapted but PBL-passaged X4 Strain III B. The
eutralizing abilities of monkey serum before immuniza-
ion, after two DNA immunizations, and after peptide
oosts were compared (Figs. 4A and 4B and Fig. 5). No
eutralization was seen before immunization. Sera from
oth monkeys neutralized isolate J2234 effectively after
wo DNA immunizations (Fig. 5A); over 90% neutralization
f 81 ID50 of J2234 was achieved with serum from Mon-
ey U9 at this time point (Fig. 5A). U9 serum after two
NA immunizations also neutralized the R5 isolate J562
Fig. 5B) but failed to neutralize the X4 strain HIV-1 III B
Fig. 5D). Isolate J562 was not neutralized by serum from
onkey B189. Neutralizing responses were enhanced by
he first peptide boost in both monkeys (Fig. 4A). No
nhancement was seen after the second peptide boost.
IgG was purified from serum after two DNA immuni-
ations of Macaque U9. Serum and purified IgG neutral-
zed HIV-1, while the IgG-depleted serum had no effect
Fig. 5C). This clearly shows that IgG was of major
mportance for neutralization.
The capacity of serum from immunized monkeys to
lock SIVsm (the virus used for challenge) infection of
ynomolgus macaque PBL was analyzed. No neutraliza-
ion was seen before immunization. After two DNA im-
unizations, over 90% neutralization was achieved with
era from both immunized monkeys (U9 and B189, Fig.
E).
-cell proliferative responses
The T-cell proliferative responses were mapped
gainst human CCR5 peptides and against membrane
ysates of CHO cells expressing human CCR5 at the
urface. Macaque B189 mounted a broad and strong
esponse already after the first immunization (Fig. 6A).
his was retained after the second immunization. At Day
2 of follow-up, the response narrowed to a moderately
trong response directed toward the N-terminus of
CR5. A specific response of Macaque U9 was not
dentified until late after the second immunization. At Day
2, we identified a strong and narrow CCR5-specific
esponse directed against the N-terminal peptide of the
last im
404 ZUBER ET AL.CCR5 protein and very similar to the late response of
Macaque B189. The T-cell proliferative responses
against all peptides used for immunization were en-
hanced in both monkeys after the second peptide boost
(Fig. 6B).
Challenge of immunized macaques
One month after the last peptide boost, the vaccinees
together with two naive control monkeys (D69 and 73–7)
FIG. 4. Time course of neutralization (NT) responses against the R5 H
N1, Table 1) of CCR5. Arrows indicate immunization events. Neutralizati
responses shown together with serum IgG toward the CCR5 N-termin
CCR5 N-terminus (B). IgA directed toward the N-terminus of CCR5 in va
peptide boost (Day 260) (C). In vitro IgG synthesis by B cells after the
using peptides (Table 1). D79 is a nonimmunized control monkey.
FIG. 5. Neutralization of two primary R5 HIV-1 isolates grown on hu
The neutralization effect of whole serum was compared to the purifie
recognizes the second extracellular loop of CCR5 and RANTES was used as a
on cynomolgus macaque PBL was also performed (E).were challenged intrarectally with 10 MID50 of SIVsm
(Quesada-Rolander et al., 1996). This SIVsm virus stock
uses CCR5 with high efficiency. BOB and Bonzo are also
used but with less efficiency (D. Vo¨dro¨s, R. Thorstensson,
G. Biberfeld, D. Schols, E. De Clerq, E. M. Fenyo¨, unpub-
lished data). The control monkeys as well as the two
vaccinees became infected as determined by virus iso-
lation, DNA PCR, and anamnestic antibody response
(data not shown). No enhancement of viral replication
late J2234 and serum antibody directed toward the N-terminus (peptide
resented as the dilution at which 50% NT was achieved. Neutralization
Neutralization responses shown together with serum IgA toward the
ashings after the first DNA immunization (Day 13) and after the second
munization (D). The response was mapped to different parts of CCR5
L: J2234 (A) and J562 (B) and one X4 isolate: III B (D) was compared.
fraction and to the same serum depleted of IgG (C). Mab 2D7 whichIV-1 iso
on is p
us (A).
ginal wman PB
d IgGpositive control (C). Neutralization of the challenge virus SIVsm grown
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406 ZUBER ET AL.was seen in the immunized compared to control ma-
caques.
MATERIALS AND METHODS
Plasmids, reagents, and virus isolates
CCR5 gene constructs. pcDNA3-CCR5 was obtained
from M. Samson, University of Brussels. To construct
pcDNA3-tet.CCR5, pcDNA3-CCR5 served as a template
for PCR using a upper 89-bp primer containing a HindIII
cloning site and 45 bases encoding a 15 amino acid
epitope (QYIKANSKFIGITEL) from the tetanus toxin. Clon-
ing sites are underlined; the tetanus epitope is shown in
bold letters: 59-CCCAAGCTTCATGCAGTACATCA-
AGGCCAACTCCAAGTTCATCGGCATCACCGAGCTG-
AGAAGCTGGAGATTATCAAGTGTCAAGTCC-39 and the
lower 31-bp primer low5tet containing a XbaI cloning
site, 59-GATTCTAGAATGAGTCCGTGTCACAAGCCCA-39.
FIG. 6. Kinetics of T-cell proliferation in vitro with PBL from vaccinate
peptides (Table 1) representing different parts of the CCR5 protein; contr
Rev 3 is a part of the HIV-1 Rev protein (A). Comparison of T-cell prolif
(nonimmunized control monkey) are shown (B). CHO–CCR5 5 membran
gene and express CCR5 on the surface; CHO 5 membrane lysates fro
ounts/min in triplicate antigen-stimulated wells by the mean counts/m
f high background in the medium wells. If the net CPM (CPM antigen 2
or PHA is 21416 (U9), 46259 (B189), and 47357 (D82).A human codon usage table based on 5,251,149 codons
was used to change the bacterial gene sequence of thetetanus epitope into triplets favored by eukaryotes. The
PCR product was cloned into pcDNA3 as a HindIII–XbaI
fragment. The new plasmid pcDNA3-tet.CCR5 contained
the tetanus epitope upstream of the CCR5 N-terminal
encoding region. E. coli DH5a was then transformed with
cDNA3-tet.CCR5. After bacterial lysis, plasmid DNA
as prepared using Plasmid MegaPrep kit (Qiagen,
ilden, Germany). The tet.CCR5 genes were sequenced
sing ABI 310 (Perkin–Elmer).
Reagents. The plasmids expressing murine GM-CSF
pCI-GM-CSF) and murine IL-4 (pCI-IL-4) were kindly
rovided by Cecilia Svanholm (Svanholm et al., 1997).
Recombinant human GM-CSF was Leucomax (Schering-
Plough, Sandoz), kindly provided by Håkan Mellstedt.
The CCR5-specific mouse Mab 2D7 was purchased from
Pharmingen (San Diego, CA). Recombinant human RAN-
TES was purchased from R&D Systems (Minneapolis,
MN).
eys. Arrows indicate immunization events. Cells were stimulated with
ides CXCR4 N and CXCR4 I1 derived from the HIV-1 coreceptor CXCR4;
s at Day 260 after the last peptide boost. Monkeys U9, B189, and D82
es from CHO cells which have been transfected with the human CCR5
cells. The stimulation index (SI) was calculated by dividing the mean
ee medium control wells. In some cases the SI becomes low because
medium) is calculated, the PHA values become quite similar. net CPMd monk
ol pept
eration
e lysat
m CHO
in in thrVirus isolates. The primary R5 HIV-1 isolates J2234 and
J562 obtained from asymptomatic patients (Jansson et
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407IMMUNE RESPONSES AGAINST THE HIV-1 CORECEPTOR CCR5al., 1996) were kindly provided by Marianne Jansson. The
X4 isolate III B passaged once in human peripheral
blood lymphocytes was kindly provided by Kajsa Aperia.
The SIVsm isolate used for challenge has been de-
scribed earlier (Quesada-Rolander et al., 1996). Virus
ID50 titration was performed essentially as described
(Albert et al., 1990). Briefly, PBL from human blood donors
were PHA stimulated for 3–5 days. A mix of PBL from two
blood donors was used in all ID50 titrations and virus
neutralization assays. Seventy-five microliters of medium
and 1 3 105 PBL in 75 ml medium were seeded in each
ell in a 96-well culture plate which was incubated for
h at 37°C. Virus aliquots were thawed and serially
iluted in threefold steps; 75 ml of each dilution was
added to five parallel wells containing medium and PBL
and incubated overnight at 37°C. The culture medium
was changed at Days 2 and 4 postinfection, and on Day
7 cell-culture medium was harvested and HIV-1 p24 was
determined using an in-house ELISA (Hinkula et al.,
1990). The ID50 value was defined as the reciprocal of
the virus dilution resulting in 50% positive wells (Reed–
Muench calculation).
Expression of CCR5 and tet.CCR5 in vitro
Chinese hamster ovary (CHO) cells were grown in
chamber slides (Nunc, Aahus, Denmark). The cells were
transfected with 2 mg of pcDNA3-CCR5 or pcDNA3-
tet.CCR5 and 3 ml of FuGENE 6 transfection reagent
Roche Diagnostics Scandinavia, Bromma, Sweden). Af-
er 48 h, the transfected cells were fixed with 2% para-
ormaldehyde. Transfected cells were visualized using a
rimary mouse anti-CCR5 monoclonal antibody (Mab
81, R&D Systems), followed by fluorescein-isothiocya-
ate (FITC)-labeled rabbit anti-mouse IgG (FO313, Dako).
HO cells constitutively expressing CCR5 (CHO-CCR5),
indly donated by M. Samson, were used as controls.
mmunization
BALB/c mouse strain. Six groups (A–F) of five 6–8
eek old BALB/c mice were immunized with 100 mg (2
mg/ml) of plasmid in 50 ml water, injected in the quadri-
eps muscle. The injected plasmids were as follows:
cDNA3 1 pCI-GM-CSF (100 mg 1 100 mg) (A), pcDNA3-
CCR5 1 pCI-GM-CSF (100 mg 1 100 mg) (B), pcDNA3-
tet.CCR5 (100 mg) (C), pcDNA3-tet.CCR5 1 pCI-GM-CSF
100 mg 1 100 mg) (D), pcDNA3-tet.CCR5 1 pCI-IL-4 (100
mg 1 100 mg) (E), and pcDNA3-CCR5 1 pCI-GM-CSF 1
CI-IL-4 (100 mg 1 50mg 1 50 mg) (F).
Two groups of five mice (G–H) were inoculated epi-
dermally at four adjacent sites of the shaved abdomen
with a total of 1 mg of gold particles coated with 4 mg of:
pcDNA3-tet.CCR5 1 pCI-GM-CSF (2 mg 1 2 mg) (G) or
cDNA3-tet.CCR5 1 pCI-GM-CSF 1 pCI-IL-4 (2 mg 1 1
mg 1 1 mg) (H) using the helium-pulsed Accell delivery
device (Geniva Inc., Middletown, WI). The mice wereimmunized at 0, 4, and 8 weeks. Blood was collected at
2-week intervals.
Cynomolgus macaques. Two cynomolgus macaques
(macaca fascicularis) (Monkeys B189 and U9), 4–5 years
old, were immunized with the plasmids pcDNA3-CCR5,
pcDNA3-tet.CCR5, and human GM-CSF protein (Leuco-
max, Schering-Plough, Sandoz) three times and then
boosted with a peptide mix twice. The plasmid/GM-CSF
mix was administered at several sites in the rectal mu-
cosa by high-pressure injection using a jet injector (Syri-
Jet markII, Mizzy Inc.). The animals were immunized at 0
(500 mg pcDNA3-CCR5 1 75 mg GM-CSF), 8 (500 mg
cDNA3-CCR5 1 75 mg GM-CSF), and 18 weeks (1000
mg pcDNA3-tet.CCR5 1 75 mg GM-CSF) with DNA.
At Weeks 31 and 35, they were boosted with a peptide
mix at several sites in the rectal mucosa using a jet
injector and intramuscularly using a syringe. A mix of
four CCR5 peptides (Table 1) (100 mg of each) represent-
ing the N-terminus (peptides N1 and N1/N2), first (pep-
tide X1), and second extracellular loops (peptide X2.2) of
CCR5 1 75 mg GM-CSF protein was administered intra-
rectally. The same mix of peptides was administered
intramuscularly together with the Ribilike (MPL 1 TDM
1 CWS) adjuvant system (Sigma); a 1-ml dose in saline
solution was administered in 500 ml into each hind leg.
D79 and D82 are nontreated control monkeys. The
acaques were housed at the Primate Research Center
t the Swedish Institute for Infectious Disease Control.
nimal handling was carried out in accordance with the
uidelines of the Swedish Ethical Committee for Animal
rotection.
ntibody assays
ELISA. Serological responses were measured by en-
yme-linked immunosorbent assay (ELISA). For all anti-
ody titer determinations, plates coated with 10 mg/ml of
peptide (Table 2) were used. The peptides were synthe-
sized by the 9-fluorenylmethoxycarbonyl method (Sall-
berg et al., 1991). ELISA was performed essentially as
described (Hinkula et al., 1997). CCR5 reactive antibod-
ies in sera were detected by horseradish peroxidase
(HRP)-labeled goat anti-human IgG or IgA (Bio-Rad, Rich-
mond, CA) or HRP-labeled goat anti-mouse IgG (Bio-
Rad). Antibody titers were calculated as the dilution
which gave an optical density (OD) that equaled the
cutoff. For cynomolgus macaques, the cutoff value was
determined for each animal as the equivalent of 3 (IgA in
serum) or 4 (IgG in serum) times the OD of sera obtained
before the primary injection.
Total IgG determination. IgG was purified from serum
and quantified essentially as described (Lundholm et al.,
1999). Briefly, IgG was purified from serum using protein
A coated beads (Biotech IgG, Denmark). IgG was quan-
tified using an ELISA.
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408 ZUBER ET AL.B-cell stimulation in vitro. CCR5-vaccinated monkeys
ere tested for circulating B cells capable of secreting
IV-1-specific antibodies when stimulated in vitro with
the antigens used for immunization. PBL (100,000/well in
200 ml RPMI 1640 supplemented with 5% inactivated
fetal calf serum) were cultured for 72 h in triplicate wells
at 37°C in 96-well, flat-bottomed cell culture plates (Nun-
clon, Nunc) coated with peptides at concentrations of 2
mg/well. After washing, the bound Ig was assayed by the
ELISAs described above.
Neutralization assay. Sera were inactivated at 56°C for
30 min and subsequently diluted in 75 ml medium in
wofold dilution steps, starting from the final dilution 1:30.
3 105 monkey or human PBL in 75 ml medium were
added to the cells and incubated at 37°C for 1 h. Then
virus in three different concentrations was added and the
plates were incubated at 37°C. After overnight incuba-
tion the cells were washed by centrifugation; this proce-
dure was repeated at day three. At day six, 100 ml of
supernatants were tested in an in-house HIV-1 p24 an-
tigen capture ELISA or an in-house SIV p26 capture
ELISA (Thorstensson et al., 1991).
An ID50 determination was made in parallel with each
neutralization test. The mean OD value of positive control
wells was considered to represent 100% of p24 release.
Percentage neutralization was calculated according to
the formula: 100 2 [100 3 (OD sample wells/OD positive
control wells)].
T-cell stimulation
T-cell stimulation was performed as described
(Hinkula et al., 1997). Briefly, mouse spleen cells
(200,000/well) were cultured in the presence of 5 mg of
antigen. Then, 3H-labeled thymidine was added and thy-
midin incorporation was measured. The stimulation in-
dex (SI) was calculated by dividing the mean counts/min
in triplicate antigen-stimulated wells by the mean counts/
min in three medium control wells. A more than twofold
increase of SI was considered positive. T-cell stimulation
was performed on monkey PBL as described, except that
5 mg of antigen were used per well (Putkonen et al.,
998). An SI over two was considered positive. In all
ests, phytohemagglutinin (PHA) or concanavalin-A
Con-A) were included as controls of cell viability.
DISCUSSION
The major role of the HIV-1 coreceptor CCR5 in pri-
ary HIV-1 infection prompted us to choose this receptor
ene as an antigen. As the CCR5 protein is difficult to
roduce in a native form for immunization, we used the
uman CCR5 gene and a modified tet.CCR5 containing a
romiscuous T-helper cell epitope in frame with the
CR5 gene. Peptide boosts were used to enhance anti-
ody responses. To successfully use the CCR5 vaccina-
ion approach in humans, tolerance to the endogenousrotein must be broken and we therefore co-immunized
ith GM-CSF (Samanci et al., 1998). Clinical trials have
hown that DNA vaccines against HIV-1 and malaria
nduce cellular and humoral responses in humans with-
ut any obvious side effects (Calarota et al., 1998;
MacGregor et al., 1998; Wang et al., 1998).
We report that naked DNA shows promise as a way to
vaccinate against the HIV-1 coreceptor CCR5. Our re-
sults demonstrate that vaccination with cDNA represent-
ing the human CCR5 gene together with the murine
GM-CSF gene elicited humoral and cellular immune re-
sponses in BALB/c mice. Cynomolgus macaques re-
sponded to immunization with the human CCR5 gene
together with human GM-CSF protein even though the
homology between the human CCR5 protein and CCR5
from cynomolgus macaques is as high as 98%. The
monkeys that developed antibody and cellular re-
sponses responded both to the human CCR5 protein and
to cynomolgus CCR5 protein. Furthermore, sera from
immunized monkeys neutralized SIVsm infection of cyno-
molgus macaque PBL. We thus suggest that tolerance
has been broken to the macaque CCR5 protein in ma-
caques. This is important when it comes to human ap-
plications. One approach to break tolerance to the en-
dogenous receptor in humans could be to immunize
them with macaque CCR5. No side effects were noted
clinically in these macaques which received both muco-
sal and intramuscular immunogens.
BALB/c mice were immunized by gene gun or intra-
muscularly with the tet.CCR5 cDNA and GM-CSF cDNA.
Gene gun covaccination with the tet.CCR5 plasmid and
GM-CSF or GM-CSF and IL-4 plasmids induced strong
antibody responses to a linear peptide representing the
N-terminus of CCR5 and moderately strong responses to
a peptide representing the second extracellular loop of
CCR5. Furthermore, we found that significant T-cell pro-
liferative responses to CCR5 peptides were induced only
by gene gun immunization.
Surprisingly, CCR5 reactive sera from the gene gun
immunized mice failed to show neutralization in a cell-
based assay. This phenomenon has been demonstrated
by others. In one study concerning DNA vaccination
against hepatitis C virus, both mice and small primates
were immunized with the same plasmids. Although an-
tibody titers in immunized mice were 10 times higher
than those in the primates, the mouse sera did not have
any neutralizing effect, while three of four immunized
primates had neutralizing antibodies (Fournillier et al.,
1999). This finding suggests that in addition to the form of
the expressed antigen, host specificity is a critical com-
ponent in the induction of biologically relevant antibod-
ies. The antibody response was much stronger toward
the N-terminus of CCR5 than to the second extracellular
loop. These findings indicate that antibodies directed to
the second extracellular loop may be more important for
neutralization than antibodies directed to the N-terminus.
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409IMMUNE RESPONSES AGAINST THE HIV-1 CORECEPTOR CCR5To enhance immune responses in macaques, the hu-
man CCR5 gene was administered together with human
GM-CSF protein. We chose to immunize the macaques
intrarectally with a novel high-pressure jet-gun delivery
technique that has been shown to induce mucosal IgA
antibodies (Lundholm et al., 1999). In both the immunized
macaques, IgG and IgA responses in serum toward a
peptide representing the N-terminal of CCR5 were de-
tected already after the first DNA immunization. Both IgG
and IgA responses toward the N-terminal peptide in-
creased several logs after the second peptide boost. The
strongest immune responses measured by in vitro B-cell
stimulation and T-cell proliferation were directed toward
the N-terminus followed by the first, second, and third
extracellular loops of human CCR5. Strong antibody re-
sponses toward the macaque CCR5 protein represented
by peptides were also demonstrated.
Antibodies directed toward the Nalterminus and the
second extracellular loop of CCR5 can neutralize HIV-1
infection of cells in vitro; monoclonal antibodies directed
toward the second extracellular loop seem to be more
effective in neutralization assays than antibodies recog-
nizing the N-terminus (Olson et al., 1999). The most
otent neutralizing Mab identified so far, 2D7, recognizes
he first part of the second extracellular loop which
eems to carry a good neutralizing epitope (Lee et al.,
999).
Although there is 98% identity between human and
ynomolgus monkey CCR5, eight amino acids differ and
our of these are located in the extracellular N-terminal
hain and second loop. The second-loop sequences of
uman and macaque CCR5 differ in amino acid 171
Table 1), which is crucial for the recognition of CCR5 by
D7 and several other Mabs. These differences may be
rucial for the macaque to recognize human CCR5 as
oreign and to elicit antibodies to the N-terminus and
econd loop of CCR5.
Strong neutralizing responses toward HIV-1 R5 strains
ere detected in both immunized macaques after two
NA immunizations. Furthermore, infection of macaque
ymphocytes by SIVsm was inhibited. Thus, immunization
ith DNA alone was sufficient to induce neutralizing
esponses in the nonhuman primate. In that DNA immu-
ization is known to induce antibodies to native
pitopes, we consider that a major part of the neutraliz-
ng effect may come from antibodies directed to confor-
ational epitopes of CCR5, especially epitopes in the
econd extracellular loop. It was also noted that the titer
f neutralization appeared to be optimal after two DNA
mmunizations and before peptide boost.
It has also been demonstrated that induction of CCR5
nhibitory antibodies is important in preventing SIV infec-
ion in macaques (Lehner et al., 1999). Based on these
ata, we reasoned that blocking CCR5 with antibodies
ould prevent infection with SIVsm or change the course
f the disease.The monkeys were challenged intrarectally with
IVsm 1 month after the last immunization. We found that
ur challenge SIVsm virus uses CCR5 more efficiently
han either BOB or Bonzo (Vo¨dro¨s et al., unpublished
ata). Others have shown that BOB plays a minor role for
he pathogenicity of the HIV-2/SIVmac/SIVsm group of
rimate lentiviruses (Pohlmann et al., 1999). After chal-
lenge, the control monkeys as well as the immunized
monkeys became infected by SIVsm, the viral load at set
point appeared quite similar. Thus, neither protection nor
enhancement was found in these two macaques. Inter-
estingly though, we have preliminary data indicating that
the virus isolates from the monkey with the highest
CCR5-specific antibody titers differs in coreceptor usage
from the virus of nonimmunized monkeys. SIVsm isolated
post challenge from Monkey U9 uses less CCR5 and
CCR3 and more of CXCR4 and BOB than the isolates
from control monkeys. These data indicate a selective
pressure from the CCR5-specific antibodies. In retro-
spect, SIVsm may not have been the optimal challenge
virus. In the next study, challenge should be made with a
SHIV containing the envelope of a R5 HIV-1.
Immunization against chemokine receptors may be of
general use in the regulation of inflammatory responses,
allergic responses, and viral diseases other than HIV-1. A
number of viruses like human cytomegalovirus and hu-
man herpesvirus Type 6 express chemokine receptor
analogues which are feasible vaccine targets. It was
recently found that CCR5-reactive antibodies in seroneg-
ative partners of HIV-1-seropositive individuals down-
modulate surface CCR5 in vivo and neutralize the infec-
tivity of R5 strains of HIV-1 in vitro (Lopalco et al., 2000).
This finding indicates that therapeutic strategies aimed
at preventing HIV-1 infection by means of antibodies to
CCR5 with a modified CCR5 gene may be feasible.
In conclusion, our results show that the human CCR5
gene is immunogenic in both mice and cynomolgus
macaques and that tolerance to endogenous CCR5
could be overcome by the use of a homologous gene for
CCR5. Antibodies induced by immunization with the hu-
man CCR5 gene could block infection of human lympho-
cytes by R5 but not X4 HIV-1 isolates.
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